Yes, but if a partner wants more data, we should produce it in a phase 3 trial and why not have a subset of subjects generate this…. now. I’m really happy to see these outcome measurements maintained, even if we are a durable pain and function drug in 2025.
I understand the costs to monitor/apply for DMOAD and the monitoring required would be financially onerous (unless a partner is sitting and waiting to strike once 2mg dose is approved, trial design is re-worked and adrenal misnomer is addressed.) F@CK knows. As KP said, no one knows (except a few that think they do).
It’s a piece of information I’ve been waiting for. This is a big moment.
I wonder if DMOAD label can be attained in Aussie TGA provisional approval?
I also wonder if a subset of phase 3 stage 2 trial subjects are outcome measured for DMOAD, whether that data can be used for accelerated approval, too.
Donna, no doubt working on all this. She is a gun. What would we do without her?
- Forums
- ASX - By Stock
- Where we at?
Yes, but if a partner wants more data, we should produce it in a...
-
- There are more pages in this discussion • 255 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 23.0¢ | $133.5K | 564.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 108916 | 23.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 58538 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 108916 | 0.235 |
11 | 91788 | 0.230 |
2 | 2260 | 0.225 |
6 | 165614 | 0.220 |
2 | 54655 | 0.215 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 58538 | 2 |
0.245 | 93762 | 5 |
0.250 | 62268 | 4 |
0.255 | 65703 | 6 |
0.260 | 122632 | 8 |
Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
Last
23.5¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
24.0¢ | 24.0¢ | 23.5¢ | 80791 | ||
Last updated 15.54pm 17/06/2024 ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online